OCS.US Oculis Holding AG Ordinary shares

Healthcare Biotechnology USA Stocks
7.63 USD
Close of Nov 16, 2026
6.78 34.48
Market cap
USD 425M
P/E
-
P/B
1.70x
ROE
-36.9%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is OCS.US undervalued?

Graham number

The Graham number of Oculis Holding AG Ordinary shares cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Oculis Holding AG Ordinary shares fundamental analysis

No fundamental analysis for Oculis Holding AG Ordinary shares yet.

Oculis Holding AG Ordinary shares stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Oculis Holding AG Ordinary shares

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; an…

Full company profile